Locoregional cytokine treatment, or immunoembolization, is an experimental targeted therapy for uveal melanoma metastatic to the liver. Unlike systemic cytokine treatments that have been associated with substantial toxicity, this method of drug delivery appears to be better tolerated. Because this newer therapy is being prescribed more widely, oncologists, interventional radiologists, cardiologists, pulmonologists, critical care specialists, and other providers should become familiar with potential adverse reactions.

We describe the case of a 67-year-old man who had metastatic uveal melanoma. Before he underwent liver-directed immunoembolization, he had elevated markers of endothelial dysfunction. He died after the rapid onset of acute right ventricular failure from severe pulmonary hypertension with possible superimposed isolated right ventricular takotsubo cardiomyopathy. In discussing this rare case, we focus on the differential diagnosis.

局部细胞因子治疗或免疫栓塞是一种针对葡萄膜黑色素瘤转移至肝脏的实验性靶向疗法。与全身性细胞因子治疗已引起明显的毒性不同，这种药物递送方法似乎具有更好的耐受性。由于这种新疗法的使用范围越来越广，因此肿瘤科医生，介入放射科医生，心脏病专家，肺科医生，重症监护专家和其他提供者应熟悉潜在的不良反应。

我们描述了一个转移性葡萄膜黑色素瘤的67岁男子的病例。在进行肝定向免疫栓塞之前，他的内皮功能障碍标志物升高。他因严重的肺动脉高压而迅速发作急性右心衰竭，并可能合并了孤立的右室takotsubo心肌病而死亡。在讨论这种罕见情况时，我们将重点放在鉴别诊断上。